ARQULE INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2014-11-12: Form 8-K; Period of report 2014-11-11; Description 8.01 Other Events; Details 8.01.
- 2014-11-10: Form 8-K; Period of report 2014-11-10; Description 8.01 Other Events; Details 8.01.
- 2014-11-10: Form 8-K; Period of report 2014-11-10; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2014-08-05: Form 8-K; Period of report 2014-07-30; Description 2.02 Results of Operations and Financial Condition; 2.05 Costs Associated with Exit or Disposal Activities; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2014-11-12 | 8-K | 2014-11-11 | 8.01 Other Events | 8.01 On November 11, 2014, ArQule, Inc. (the “Registrant”) issued a press release announcing a collaboration with the National Institutes of Health for the clinical development of ARQ 092, an orally available, selective small molecule inhibitor of AKT, in Proteus syndrome. | t80711_8k.htm |
| 2014-11-10 | 8-K | 2014-11-10 | 8.01 Other Events | 8.01 On November 10, 2014, ArQule, Inc. (the “Registrant”) issued a press release announcing the top-line results of a single agent trial of tivantinib sponsored by the National Cancer Institute (NCI) in metastatic prostate cancer. | t80697_8k.htm |
| 2014-11-10 | 8-K | 2014-11-10 | 2.02 Results of Operations and Financial Condition | 2.02 On November 10, 2014, ArQule, Inc. (the “Registrant”) issued a press release announcing its results of operations for the fiscal quarter ended September 30, 2014. | t80695_8k.htm |
| 2014-08-05 | 8-K | 2014-07-30 | 2.02 Results of Operations and Financial Condition; 2.05 Costs Associated with Exit or Disposal Activities | 2.02 On August 5, 2014, ArQule, Inc. (the “Registrant” or the “Company”) issued a press release announcing (i) its results of operations for the fiscal quarter ended June 30, 2014 and (ii) a focused reduction in its workforce. 2.05 On July 30, 2014, the Company approved plans to restructure its operations to better align its human and financial resources with the Company’s primary focus on clinical stage development programs and to extend the Company’s cash runway beyond the anticipated time for achievement of key milestones, including the completion of the METIV-HCC trial. | t79909_8k.htm |
| 2014-05-30 | 8-K | 2014-05-30 | 8.01 Other Events | 8.01 On May 30, 2014, ArQule, Inc. (the “Registrant”) announced that tivantinib will be included in seven presentations during the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held from May 30 to June 3 in Chicago, Illinois. | t79460_8k.htm |
| 2014-05-16 | 8-K | 2014-05-13 | 5.07 Submission of Matters to a Vote of Security Holders | t79341_8k.htm | |
| 2014-05-07 | 8-K | 2014-05-07 | 2.02 Results of Operations and Financial Condition | 2.02 On May 7, 2014 ArQule, Inc. (the “Registrant”) issued a press release announcing its results of operations for the fiscal quarter ended March 31, 2014. | t1400855_8k.htm |
| 2014-03-05 | 8-K | 2014-03-05 | 2.02 Results of Operations and Financial Condition | 2.02 On March 5, 2014 ArQule, Inc. (the “Registrant”) issued a press release announcing its results of operations for the fiscal quarter and year ended December 31, 2013. | t78514_8k.htm |
| 2014-02-04 | 8-K | 2014-02-04 | 8.01 Other Events | 8.01 On February 4, 2014, ArQule, Inc. (the "Registrant") reported the announcement by its development partner, Kyowa Hakko Kirin Co., Ltd., of the initiation of a Phase 3 clinical trial evaluating tivantinib (ARQ 197) in Japanese patients with c-Met diagnostic-high inoperable hepatocellular carcinoma treated with one prior sorafenib therapy. | t78196_8k.htm |
| 2014-01-27 | 8-K | 2014-01-22 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 On January 22, 2014, the Board of Directors (the “Board”) of ArQule, Inc. (the “Registrant”) revised Sections 7, 8, 10 and 11 of Article II of the Registrant’s Amended and Restated Bylaws (“Bylaws”). | t78146_8k.htm |
| 2014-01-16 | 8-K | 2014-01-16 | 8.01 Other Events | t78108_8k.htm |